Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Fennec Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Fennec Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2023 was 94.1%. For fiscal 2023 it was 94.1%, against 94.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 94.1% | −0.3 |
| FY2022 | Dec 31, 2022 | 94.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | 93.0% | – |
| Q3 FY2023 | Sep 30, 2023 | 94.9% | – |
| Q2 FY2023 | Jun 30, 2023 | 95.5% | – |
| Q1 FY2023 | Mar 31, 2023 | 94.3% | – |
See a number that looks wrong?